Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Breast Neoplasms 26 Triple Negative Breast Neoplasms 13 Prostatic Neoplasms 12 Ovarian Neoplasms 12 Neoplasms 10 Neoplasm Metastasis 8 Fallopian Tube Neoplasms 6 Leukemia, Myeloid, Acute 5 Small Cell Lung Carcinoma 4 Pancreatic Neoplasms 4 Endometrial Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Solid Tumors 4 Carcinoma, Renal Cell 3 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Sarcoma, Ewing 2 Recurrence 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Lung Neoplasms 2 Carcinoma, Ovarian Epithelial 2 mCRPC 1 Wilms Tumor 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Triple Negative Metastatic Breast Cancer 1 Thrombocythemia, Essential 1 Solid Tumor 1 Sarcoma 1

Interventions

lutetium Lu 177 dotatate 34 Everolimus 33 lanreotide 13 gallium Ga 68 dotatate 13 Temozolomide 13 Magnetic Resonance Spectroscopy 13 Nivolumab 12 pembrolizumab 11 Octreotide 11 Capecitabine 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 10 cabozantinib 9 Positron Emission Tomography Computed Tomography 9 3-Iodobenzylguanidine 9 surufatinib 8 Sunitinib 8 Specimen Handling 7 Carboplatin 7 pasireotide 6 amino-acid, glucose, and electrolyte solution 6 90Y-octreotide, DOTA-Tyr(3)- 6 lenvatinib 5 Lutetium-177 5 Ipilimumab 5 Fluorodeoxyglucose F18 5 Etoposide 5 Cisplatin 5 Bevacizumab 5 telotristat ethyl 4 olaparib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neuroendocrine Tumors × talazoparib × Clear all

NCT05053854 2025-02-20

PARLuNET

Peter MacCallum Cancer Centre, Australia

Phase 1 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡